(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
NCT07680244
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Epiretinal Membrane
- Dry Age Related Macular Degeneration
- Macular Abnormalities
- Retina Disease
- Vitreoretinal Abnormality
- Intraretinal Hyporeflective Space
- Subretinal Hyporeflective Space
- IS/OS (Ellipsoid Zone) Disruption
- Retinal Pigment Epithelium (RPE) Elevation
- Retinal Pigment Epithelium (RPE) Atrophy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
- Last updated on ClinicalTrials.gov
- August 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Retina Associates · Tucson, AZ
California · 1
- Northern California Retina Vitreous Associates · Mountain View, CA
Florida · 1
- Nova Southeastern University College of Optometry · Fort Lauderdale, FL
Maine · 1
- Eyecare Medical Group · Portland, ME
Missouri · 1
- Moyes Eye Center · Kansas City, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.